AnalystsJohn WilkinJohn Wilkin's Stock Forecasts
AnalystsJohn Wilkin
Sectors:
Industries:
Analyst Ranking
Top 35%
#1782 out of 5116 analysts
Average Return
+57.01%
Win Rate
80%4 out of 5
Risk vs Reward
Poor
Good
John Wilkin's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Personalis IncPSNL | +182.37% | $3.80 | $10.73 | 2025-03-17 - 2025-11-28 | Buy |
Adaptive Biotechnologies CorpADPT | +87.77% | $10.47 | $19.66 | 2025-06-18 - 2025-11-28 | Buy |
Veracyte IncVCYT | +48.68% | $31.84 | $47.34 | 2025-03-20 - 2025-11-28 | Buy |
Exagen IncXGN | +7.92% | $7.32 | $7.90 | 2025-07-23 - 2025-11-28 | Buy |
John Wilkin Analyst Color
Get additional color on John Wilkin's coverage of popular stocks
John Wilkin's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Exagen IncXGN | 1 | Buy | $12.00 | +51.90% | Initiates Coverage On | 4 months ago |
Adaptive Biotechnologies CorpADPT | 1 | Buy | $15.00 | -23.70% | Initiates Coverage On | 5 months ago |
Veracyte IncVCYT | 1 | Buy | $45.00 | -4.94% | Initiates Coverage On | 8 months ago |
Personalis IncPSNL | 1 | Buy | $8.00 | -25.44% | Initiates Coverage On | 8 months ago |
Myriad Genetics IncMYGN | 1 | Buy | $29.00 | +280.08% | Initiates Coverage On | 10 months ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.